These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 15930363

  • 1. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M, Spernyak JA, Mazurchuk R, Camacho SH, Oseroff AR, Cheney RT, Bellnier DA.
    Clin Cancer Res; 2005 Jun 01; 11(11):4241-50. PubMed ID: 15930363
    [Abstract] [Full Text] [Related]

  • 2. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT.
    Cancer Res; 2003 Nov 15; 63(22):7584-90. PubMed ID: 14633671
    [Abstract] [Full Text] [Related]

  • 3. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo.
    Seshadri M, Bellnier DA.
    Photochem Photobiol; 2009 Nov 15; 85(1):50-6. PubMed ID: 18643909
    [Abstract] [Full Text] [Related]

  • 4. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
    McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR, Robinson SP.
    Clin Cancer Res; 2005 May 15; 11(10):3705-13. PubMed ID: 15897567
    [Abstract] [Full Text] [Related]

  • 5. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM.
    Cancer Res; 2005 Dec 15; 65(24):11752-61. PubMed ID: 16357188
    [Abstract] [Full Text] [Related]

  • 6. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
    Henderson BW, Sitnik-Busch TM, Vaughan LA.
    Photochem Photobiol; 1999 Jul 15; 70(1):64-71. PubMed ID: 10420844
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM.
    Cancer Res; 2001 Aug 01; 61(15):5824-32. PubMed ID: 11479222
    [Abstract] [Full Text] [Related]

  • 8. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 9. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F, Liu J, Ching LM, Baguley BC.
    Cancer Chemother Pharmacol; 2008 Mar 01; 61(3):497-502. PubMed ID: 17473922
    [Abstract] [Full Text] [Related]

  • 10. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
    Zhao L, Ching LM, Kestell P, Baguley BC.
    Clin Cancer Res; 2003 Dec 15; 9(17):6545-50. PubMed ID: 14695159
    [Abstract] [Full Text] [Related]

  • 11. Photodynamic therapy: a means to enhanced drug delivery to tumors.
    Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW.
    Cancer Res; 2003 Dec 01; 63(23):8126-31. PubMed ID: 14678965
    [Abstract] [Full Text] [Related]

  • 12. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Horsman MR.
    Int J Hyperthermia; 2004 Jun 01; 20(4):393-404. PubMed ID: 15204520
    [Abstract] [Full Text] [Related]

  • 13. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.
    Busch TM, Wileyto EP, Emanuele MJ, Del Piero F, Marconato L, Glatstein E, Koch CJ.
    Cancer Res; 2002 Dec 15; 62(24):7273-9. PubMed ID: 12499269
    [Abstract] [Full Text] [Related]

  • 14. Chlorophyll-a analogues conjugated with aminobenzyl-DTPA as potential bifunctional agents for magnetic resonance imaging and photodynamic therapy.
    Li G, Slansky A, Dobhal MP, Goswami LN, Graham A, Chen Y, Kanter P, Alberico RA, Spernyak J, Morgan J, Mazurchuk R, Oseroff A, Grossman Z, Pandey RK.
    Bioconjug Chem; 2005 Dec 15; 16(1):32-42. PubMed ID: 15656573
    [Abstract] [Full Text] [Related]

  • 15. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
    McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB.
    Clin Cancer Res; 2006 Mar 15; 12(6):1776-84. PubMed ID: 16551862
    [Abstract] [Full Text] [Related]

  • 16. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM.
    Cancer Res; 1999 Feb 01; 59(3):633-8. PubMed ID: 9973211
    [Abstract] [Full Text] [Related]

  • 17. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
    Engbrecht BW, Menon C, Kachur AV, Hahn SM, Fraker DL.
    Cancer Res; 1999 Sep 01; 59(17):4334-42. PubMed ID: 10485481
    [Abstract] [Full Text] [Related]

  • 18. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z, Baguley BC, Ching LM.
    Cancer Res; 2001 Feb 15; 61(4):1517-21. PubMed ID: 11245459
    [Abstract] [Full Text] [Related]

  • 19. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer.
    Takeuchi Y, Kurohane K, Ichikawa K, Yonezawa S, Nango M, Oku N.
    Cancer; 2003 Apr 15; 97(8):2027-34. PubMed ID: 12673734
    [Abstract] [Full Text] [Related]

  • 20. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B.
    Cancer Chemother Pharmacol; 2005 Dec 15; 56(6):569-77. PubMed ID: 16001166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.